235 related articles for article (PubMed ID: 32573116)
41. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
42. Multi-Compartment Spatially-Derived Radiomics From Optical Coherence Tomography Predict Anti-VEGF Treatment Durability in Macular Edema Secondary to Retinal Vascular Disease: Preliminary Findings.
Sil Kar S; Sevgi DD; Dong V; Srivastava SK; Madabhushi A; Ehlers JP
IEEE J Transl Eng Health Med; 2021; 9():1000113. PubMed ID: 34350068
[TBL] [Abstract][Full Text] [Related]
43. Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema.
Campos A; Campos EJ; do Carmo A; Patrício M; Castro de Sousa JP; Ambrósio AF; Silva R
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1857-1865. PubMed ID: 30039271
[TBL] [Abstract][Full Text] [Related]
44. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
Kaya M; Karahan E; Ozturk T; Kocak N; Kaynak S
Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
[TBL] [Abstract][Full Text] [Related]
46. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.
Weiss M; Sim DA; Herold T; Schumann RG; Liegl R; Kern C; Kreutzer T; Schiefelbein J; Rottmann M; Priglinger S; KortUEm KU
Retina; 2018 Dec; 38(12):2293-2300. PubMed ID: 29068914
[TBL] [Abstract][Full Text] [Related]
47. Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study.
Farinha C; Martins A; Neves A; Soares R; Ruão M; Ornelas M; Neves P; Gomes Rodrigues F; Coelho C; Silva R
Ophthalmologica; 2019; 241(1):1-8. PubMed ID: 29886497
[TBL] [Abstract][Full Text] [Related]
48. Effect of diabetic macular edema on peripapillary retinal nerve fiber layer thickness profiles.
Hwang DJ; Lee EJ; Lee SY; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2014 May; 55(7):4213-9. PubMed ID: 24833740
[TBL] [Abstract][Full Text] [Related]
49. Association Between Hyperreflective Dots on Spectral-Domain Optical Coherence Tomography in Macular Edema and Response to Treatment.
Hwang HS; Chae JB; Kim JY; Kim DY
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5958-5967. PubMed ID: 29183041
[TBL] [Abstract][Full Text] [Related]
50. Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity.
Busch C; Okada M; Zur D; Fraser-Bell S; Rodríguez-Valdés PJ; Cebeci Z; Lupidi M; Fung AT; Gabrielle PH; Giancipoli E; Chaikitmongkol V; Laíns I; Santos AR; Kunavisarut P; Sala-Puigdollers A; Chhablani J; Ozimek M; Hilely A; Degenhardt V; Loewenstein A; Iglicki M; Rehak M;
Acta Ophthalmol; 2020 Nov; 98(7):e801-e806. PubMed ID: 32115886
[TBL] [Abstract][Full Text] [Related]
51. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema.
Ebneter A; Waldmeier D; Zysset-Burri DC; Wolf S; Zinkernagel MS
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):549-555. PubMed ID: 27714513
[TBL] [Abstract][Full Text] [Related]
52. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.
Laugesen CS; Ostri C; Brynskov T; Lund-Andersen H; Larsen M; Vorum H; Sørensen TL
Acta Ophthalmol; 2017 Feb; 95(1):28-32. PubMed ID: 27473397
[TBL] [Abstract][Full Text] [Related]
53. Optical Coherence Tomography Angiography Analysis of the Foveal Avascular Zone and Macular Vessel Density After Anti-VEGF Therapy in Eyes With Diabetic Macular Edema and Retinal Vein Occlusion.
Ghasemi Falavarjani K; Iafe NA; Hubschman JP; Tsui I; Sadda SR; Sarraf D
Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):30-34. PubMed ID: 28114569
[TBL] [Abstract][Full Text] [Related]
54. Intracystic hyperreflective material in centre-involving diabetic macular oedema.
Venkatesh R; Sangai S; Reddy NG; Sridharan A; Pereira A; Aseem A; Gadde SGK; Yadav NK; Chhablani J
Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2533-2544. PubMed ID: 33710472
[TBL] [Abstract][Full Text] [Related]
55. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
[TBL] [Abstract][Full Text] [Related]
56. VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS.
Seo KH; Yu SY; Kim M; Kwak HW
Retina; 2016 Mar; 36(3):588-95. PubMed ID: 26398695
[TBL] [Abstract][Full Text] [Related]
57. DETECTION OF MORPHOLOGIC PATTERNS OF DIABETIC MACULAR EDEMA USING A DEEP LEARNING APPROACH BASED ON OPTICAL COHERENCE TOMOGRAPHY IMAGES.
Wu Q; Zhang B; Hu Y; Liu B; Cao D; Yang D; Peng Q; Zhong P; Zeng X; Xiao Y; Li C; Fang Y; Feng S; Huang M; Cai H; Yang X; Yu H
Retina; 2021 May; 41(5):1110-1117. PubMed ID: 33031250
[TBL] [Abstract][Full Text] [Related]
58. Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.
Chatziralli I; Santarelli M; Patrao N; Nicholson L; Zola M; Rajendram R; Hykin P; Sivaprasad S
Eye (Lond); 2017 Nov; 31(11):1594-1599. PubMed ID: 28622321
[TBL] [Abstract][Full Text] [Related]
59. Yearly Treatment Patterns for Patients with Recently Diagnosed Diabetic Macular Edema.
Moulin TA; Adjei Boakye E; Wirth LS; Chen J; Burroughs TE; Vollman DE
Ophthalmol Retina; 2019 Apr; 3(4):362-370. PubMed ID: 31014689
[TBL] [Abstract][Full Text] [Related]
60. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
Sonoda Y; Arimura N; Shimura M; Sakamoto T
Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
